Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?

Current Atherosclerosis Reports

Volumn 9, Issue 5, 2007, Pages 375-383

  Maron, Bradley A ^b   Loscalzo, Joseph ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; RESTENOSIS; REVIEW; SECONDARY PREVENTION; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ARTERIOSCLEROSIS; DISEASE SUSCEPTIBILITY; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 36148936770     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-007-0048-x     Document Type: Review

References (69)

1. Deitcher SR, Jaff MR: Pharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med 2002, 3(Suppl 2):S25-33.
2. Yusuf S, Reddy S, Ounpuu S, Anand S: Global burden of cardiovascular disease, I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104:2746-2753.
3. Coronary Drug Project Research Group: Natural history of myocardial infarction in the coronary drug project: long term implications of serum lipid levels. Am J Cardiol 1978, 30:489-498.
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
5. McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
6. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
7. Lonn E, Yusuf S, Arnold MJ, et al.: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
8. Bønna KH, Njolstad I, Ueland PM, et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.
9. Toole JF, Malinow MR, Chambless LE, et al.: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-575.
10. Champe P, Harvey R: Amino acids: metabolism of carbon skeletons. In Lippincott's Illustrated Reviews: Biochemistry, 2nd edition. Edited by Champe P, Harvey R. Philadelphia: JB Lippincott; 1987:248-249.
11. Finkelstein JD: Methionine metabolism in mammals. J Nutr Biochem 1990, 1:228-237.
12. Malinow R, Bostom AG, Krauss RM: Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999, 99:178-182.
13. Jacques PF, Bostom AG, Williams RR, et al.: Relation between folate status, a common mutation in methylene-tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9.
14. Brattstrom L, Wilcken DE, Ohrvik J, et al.: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998, 98:2520-2256.
15. Kolling K, Ndrepepa G, Koch W, et al.: Methylene-tetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol 2004, 93:1201-1206.
16. Garovic-Kocic V, Rosenblatt DS: Methionine auxotrophy in inborn errors of cobalamin metabolism. Clin Invest Med 1995, 15:395-400.
17. Kraus JP, Kozich V. Cystathionine b-synthase and its deficiency. In Homocysteine in Health and Disease. Edited by Carmel R, Jacobsen DW. New York: Cambridge University Press; 2001:223-244.
18. Watanabe M, Osada J, Aratani Y, et al.: Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci U S A 1995, 92:1585-1589.
19. Eberhardt RT, Fogione MA, Cap A, et al.: Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000, 106:483-491.
20. Ghandour H, Chen Z, Selhub J, et al.: Mice deficient in methylenetetrahydrofolate reductase exhibit tissue-specific distribution of folates. J Nutr 2004, 134:2975-2980.
21. Chen Z, Karaplis AC, Ackerman SL, et al.: Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001, 10:433-443.
22. Maron BA, Loscalzo J: Homocysteine. Clin Lab Med 2006, 26:591-609.
23. Tropodi A, Chantarangkul V, Lombardi R, et al.: Multicenter study of homocysteine measurement-performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost 2002, 87:921-922.
24. Mourvaki E, Ferrante F, Chirarduzzi A, et al.: Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease. Am J Clin Pathol 2005, 124:675-681.
25. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998, 9(Suppl 12):16-23.
26. Refsum H, Smith D, Ueland P, et al.: Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004, 50:3-32.
27. Weiss N, Keller C, Hoffmann U, Loscalzo J: Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2003, 7:227-239.
28. Libby P, Ridker PM: Inflammation and atherothrombosis from population biology and bench research to clinical practice. J Am Coll Cardiol 2006, 7:48(Suppl 9):A33-46.
29. Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868-874.
30. Inoue S, Egashira K, Ni W, et al.: Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002, 19:2700-2706.
31. Xu XH, Shah PK, Faure E, et al.: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
32. Zmijewski JW, Moellering DR, Le Goffe C, et al.: Oxidized LDL induces mitochondrially associated reactive oxygen/nitrogen species formation in endothelial cells. Am J Physiol Heart Circ Physiol 2005, 289:H852-861.
33. Peng HB, Libby P, Liao JK: Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995, 270:14214-14219.
34. Loscalzo J: Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001, 88:756-762.
35. de Nigris F, Lerman LO, Ignarro SW, et al.: Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. Proc Natl Acad Sci U S A 2003, 100:1420-1425.
36. Welch GN, Upchurch GR, Farivar RS, et al.: Homocysteine-induced nitric oxide production in vascular-smooth muscle cells by NF-kB-dependent transcriptional activation of Nos2. Proc Assoc Am Phys 1998, 110:22-31.
37. Loscalzo J: The oxidant stress of hyperhomocyst(c)inemia. J Clin Invest 1996, 98:5-7.
38. Handy DE, Zhang Y, Loscalzo J: Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 2005, 280:15518-15525.
39. Weiss N, Zhang YY, Heydrick S, et al.: Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S A 2001, 98:12503-12508.
40. Bellamy MF, McDowell IF, Ramsey MW, et al.: Hyper-homocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998, 98:1848-1852.
41. Zhou J, Werstuck GH, Lhotak S, et al.: Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation 2004, 110:207-213.
42. Carmel R: Folate deficiency. In Homocysteine in Health and Disease. Edited by Carmel R, Jacobsen DW. New York: Cambridge University Press; 2001:271-288.
43. Babior BM, Bunn FH: Meagaloblastic anemias. In Harrison's Principles of Internal Medicine, 16th edition. Edited by Longo DL. New York: McGraw-Hill Press; 2005:601-607.
44. Hiltunen MO, Yia-Herttuala S: DNA methylation, smooth muscle cells, and atherogenesis. Arterioscler Thromb Vasc Biol 2003, 23:1750-1753.
45. Loscalzo J: Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 2006, 354:1629-1632.
46. Jacques PF, Selhub J, Bostorn AG, et al.: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999, 340:1449-1454.
47. MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991, 338:131-137.
48. Refsum H, Ueland PM, Nygård O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998, 49:31-62.
49. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775-1781.
50. Nygård O, Norderhaug JE, Refsum H, et al.: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230-236.
51. Wang TJ, Gona P, Larson M, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
52. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke; a meta-analysis. JAMA 2002, 288:2015-2022.
53. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202-1209.
54. Schynder G, Roffi M, Pin R, et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345:1593-1600.
55. Schnyder G, Roffi M, Flammer Y, et al.: Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol 2003, 91:1265-1269.
56. Lange H, Surapranata H, De Luca G, et al.: Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004, 350:2673-2681.
57. Kaul S, Zadeh AA, Shah PK: Homocysteine hypothesis for atherothrombotic cardiovascular disease, not validated. J Am Coll Cardiol 2006, 48:914-923.
58. Bazzano LA, Renolds K, Holder KN, He J: Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006, 296:2720-2726.
59. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al.: Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003, 41:2105-2113.
60. Selhub J: The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 2006, 136(Suppl 6):1726S-1730S.
61. Clarke R, Daly L, Robinson K, et al.: Hyperhomocysteinemia and independent risk factor for vascular disease. N Engl J Med 1991, 324:1149-1155.
62. Harker LA, Slichter SJ, Scott CR, et al.: Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974, 291:537-541.
63. Harker LA, Harlan JM, Ross R: Effect of sulfinpyrazone on homocysteine-induced injury and atherosclerosis in baboons. Circ Res 1983, 53:731-738.
64. Jakubowski H: Biosynthesis and reactions of homocysteine thiolactone. In Homocysteine in Healtb and Disease. Edited by Carmel R, Jacobsen DW. New York: Cambridge University Press; 2001:21-31.
65. Heinecke JW: Unique aspects of sulfur chemistry: homocysteine and lipid oxidation. In Homocysteine in Health and Disease. Edited by Carmel R, Jacobsen DW. New York: Cambridge University Press; 2001:32-38.
66. Villareal DT, Miller BV 3rd, Banks M, et al.: Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. Am J Clin Nutr 2006, 84:1317-1327.
67. Halton TL, Willett WC, Liu S, et al.: Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med 2006, 355:1991-2002.
68. Yang Q, Botto LD, Erickson D, et al.: Improvement in stroke mortality in Canada and the United States, 1990-2002. Circulation 2006, 113:1335-1343.
69. Rasouli ML, Khurram N, Blumenthal RS, et al.: Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis 2005, 181:159-165.